All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2021; the latest 2025-08-29.
From the record
Century Therapeutics, Inc.'s filings since 2021 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2025-08-29) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+175.8% a year over 4 filed years; profitable in 0 of 4.
From the record
Century Therapeutics, Inc.'s 4 filed years say what it did: revenue went from $5 million in fiscal 2022 to $109 million in fiscal 2025, up 175.8% a year; it rose in 2 of 3 years; the deepest fall was 57% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.4/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Century Therapeutics, Inc.'s shareholder treatment is put at 3.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 34% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -6%: lost 6¢ per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Century Therapeutics, Inc. lost about 6 cents for every dollar of shareholders' money. Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count grew 10.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 20% of 102 in its family; net margin -8.8%.
From the record
Century Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $109 million in fiscal 2025 ranks in the top 29% by size; a net margin of -8.8% ranks in the top 23%; revenue growth of 175.8% a year over the last 3 filed years ranks in the top 8% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 21% of 110 in its family for leadership; chief executive since 2023.
From the record
Century Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Pfeiffenberger, Brent (President and CEO, as filed), filing under that title since 2023-12-06, 2.9 years (bottom 32% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 3.5 years (bottom 18%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 15%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 49% of 92 in its family for room to expand.
From the record
Century Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $65 million against no long-term debt tagged leaves 29.1% of its assets as net cash, top 48% of its family; cash from operations less capital spending is -95.9% of revenue (top 37%); research spending of 87.6% of revenue (bottom 38%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 46% of 100 in its family for growth drivers.
From the record
Century Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 175.8% a year over the last three filed years against 175.8% over all 4, speeding up (top 36% of its family); the newest year grew 1560% (top 2%); research spending grew -0.5% a year (bottom 47%); capital spending grew -69.7% a year (bottom 8%) (its annual reports). Century Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 10% of 72 in its family for expectations against reality.
From the record
Century Therapeutics, Inc.'s newest year against its own record: revenue of $109 million in fiscal 2025 came in 1371.8% above the $7 million its prior three years' pace pointed to (top 4% of its family); net income of $10 million against a prior three-year average of $131 million (top 17%); a net margin of -8.8% against losses larger than its revenue before (top 10%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made